OBJECTIVES: We aim to report oncologic outcomes after conventional radiotherapy (ConRT) using opposed lateral beams and intensity-modulated radiation therapy (IMRT) for tumor (T)1 nodal (N)0 T1 N0 glottic squamous cell carcinoma. STUDY DESIGN: Retrospective case-control study. METHODS: We retrospectively reviewed demographic, disease, and treatment characteristics for patients treated at our institution during 2000 to 2013. RESULTS: One hundred fifty-three patients (71%) were treated using ConRT and 62 (29%) using IMRT. The median follow-up for all patients was 68 months. There was no statistically significant difference in 5-year local control between patients with T1a versus T1b disease (94% vs. 89%, respectively, P = 0.5). Three-year locoregional control for patients treated with ConRT was 94% compared to 97% with IMRT (P = 0.4). Three-year overall survival (OS) for patients treated with ConRT was 92.5% compared with 100% with IMRT (P = 0.1). Twelve of 14 patients with local recurrence underwent salvage surgery with 5-year ultimate locoregional control of 98.5% and 97.1% in the ConRT and IMRT cohorts, respectively (P = 0.7). Multivariate analysis showed age < 60 years (P < 0.0001) and pretreatment Eastern Cooperative Oncology Group performance status <2 (P = 0.0022) to be independent correlates of improved OS. Postradiation cerebrovascular events were in four patients in the ConRT cohort (3%), whereas no patients in the IMRT cohort suffered any events. CONCLUSION: Because the oncologic outcomes for patients treated with IMRT were excellent and IMRT allows for carotid sparing, we have transitioned to IMRT as our standard for most patients with T1 glottic cancer. LEVEL OF EVIDENCE: 3b Laryngoscope, 130:146-153, 2020.
OBJECTIVES: We aim to report oncologic outcomes after conventional radiotherapy (ConRT) using opposed lateral beams and intensity-modulated radiation therapy (IMRT) for tumor (T)1 nodal (N)0 T1 N0 glottic squamous cell carcinoma. STUDY DESIGN: Retrospective case-control study. METHODS: We retrospectively reviewed demographic, disease, and treatment characteristics for patients treated at our institution during 2000 to 2013. RESULTS: One hundred fifty-three patients (71%) were treated using ConRT and 62 (29%) using IMRT. The median follow-up for all patients was 68 months. There was no statistically significant difference in 5-year local control between patients with T1a versus T1b disease (94% vs. 89%, respectively, P = 0.5). Three-year locoregional control for patients treated with ConRT was 94% compared to 97% with IMRT (P = 0.4). Three-year overall survival (OS) for patients treated with ConRT was 92.5% compared with 100% with IMRT (P = 0.1). Twelve of 14 patients with local recurrence underwent salvage surgery with 5-year ultimate locoregional control of 98.5% and 97.1% in the ConRT and IMRT cohorts, respectively (P = 0.7). Multivariate analysis showed age < 60 years (P < 0.0001) and pretreatment Eastern Cooperative Oncology Group performance status <2 (P = 0.0022) to be independent correlates of improved OS. Postradiation cerebrovascular events were in four patients in the ConRT cohort (3%), whereas no patients in the IMRT cohort suffered any events. CONCLUSION: Because the oncologic outcomes for patients treated with IMRT were excellent and IMRT allows for carotid sparing, we have transitioned to IMRT as our standard for most patients with T1 glottic cancer. LEVEL OF EVIDENCE: 3b Laryngoscope, 130:146-153, 2020.
Authors: Sarah O S Osman; Eleftheria Astreinidou; Hans C J de Boer; Fatma Keskin-Cambay; Sebastiaan Breedveld; Peter Voet; Abrahim Al-Mamgani; Ben J M Heijmen; Peter C Levendag Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-06 Impact factor: 7.038
Authors: Paul D Brown; Robert L Foote; Mark P McLaughlin; Michele Y Halyard; Karla V Ballman; A Craig Collie; Robert C Miller; Kelly D Flemming; John W Hallett Journal: Int J Radiat Oncol Biol Phys Date: 2005-09-19 Impact factor: 7.038
Authors: S G Laskar; G Baijal; V Murthy; S Chilukuri; A Budrukkar; T Gupta; J P Agarwal Journal: Clin Oncol (R Coll Radiol) Date: 2012-08-03 Impact factor: 4.126
Authors: J Cacicedo; F Casquero; O del Hoyo; A Gomez-Iturriaga; L Martinez-Indart; J L Lopez; P Bilbao Journal: Clin Transl Oncol Date: 2013-03-22 Impact factor: 3.405
Authors: Charles A Baron; Musaddiq J Awan; Abdallah S R Mohamed; Imad Akel; David I Rosenthal; G Brandon Gunn; Adam S Garden; Brandon A Dyer; Laurence Court; Parag R Sevak; Esengul Kocak-Uzel; Clifton D Fuller Journal: J Appl Clin Med Phys Date: 2014-01-08 Impact factor: 2.102
Authors: Karine A Al Feghali; Bassem Y Youssef; Abdallah S R Mohamed; Lara Hilal; Blaine D Smith; Ibrahim Abu-Gheida; Georges Farha; G Brandon Gunn; Jack Phan; Jan Lewin; Apurva Thekdi; William H Morrison; Adam S Garden; Clifton David Fuller; David I Rosenthal Journal: Head Neck Date: 2020-06-02 Impact factor: 3.147
Authors: Ellen J L Brunenberg; Isabell K Steinseifer; Sven van den Bosch; Johannes H A M Kaanders; Charlotte L Brouwer; Mark J Gooding; Wouter van Elmpt; René Monshouwer Journal: Phys Imaging Radiat Oncol Date: 2020-07-10
Authors: Mark C Korpics; W Tyler Turchan; Michael K Rooney; Matthew Koshy; Michael T Spiotto Journal: Cancers (Basel) Date: 2019-12-12 Impact factor: 6.639